A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

Clinical trial NCT04104776 · RECRUITING

Trial details

NCT number: NCT04104776
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumor Diffuse Large B Cell Lymphoma Lymphoma, T-Cell Mesothelioma, Malignant Prostatic Neoplasms, Castration-Resistant Endometrial Cancer Ovarian Clear Cell Carcinoma Metastatic Castration-resistant Prostate Cancer

Start date: 2019-09-18
Primary completion: 2030-02-27
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.